LIPOPHARMA THERAPEUTICS SL

LIPOPHARMA THERAPEUTICS SL

Lipoharma is a clinical-stage biopharmaceutical company based in Mallorca (Spain) that focuses on the discovery, design and clinical development of potentially transformative novel products that specifically interact with key signal transduction proteins (at membrane level) involved in the pathogenesis of serious diseases. Lipopharma arose in 2006 as an academic spin-off of the cellular and molecular biomedicine research group at the University of the Balearic Islands (UIB). Lipopharma aims to develop next-generation medicines, as well as nutraceutical and cosmetic products, on the basis of the novel Membrane-Lipid Therapy (MLT) strategy, which implies the regulation of the activity of key membrane associated signal transduction proteins, through the modulation of the structure and organization of the membrane lipid micro-domains (nanoclustering) involved in cell signalling. Innovative MLT-based drugs will soon become reference treatments worldwide for serious diseases with important medical needs w, such as glioblastoma and other aggressive cancer malignancies, Alzheimer's disease, Spinal Cord Injury, metabolic, cardiovascular or inflammatory diseases, providing a safe and efficacious therapeutic alternative that will bring dramatic improvements in the clinical outcome and in the quality of life for an important number of patients with these pathologies.